octreotide pamoate

DRUG3 trials

Sponsors

NSABP Foundation Inc, Novartis Pharmaceuticals, University of Southern California

Conditions

Breast CancerDiarrheaHealthy CholecystectomizedHormone-resistant Prostate CancerRecurrent Prostate CancerStage I Prostate CancerStage IIA Prostate CancerStage IIB Prostate Cancer

Phase 1

Open Label Study of a Single Dose of a New Extended Long Acting Formulation of Octreotide Pamoate in Healthy Volunteers

CompletedNCT00432068

Novartis PharmaceuticalsHealthy Cholecystectomized

Start: 2007-01-31End: 2010-06-30Updated: 2015-12-03

Phase 2

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

TerminatedNCT01469338

University of Southern CaliforniaDiarrhea, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer +5

Start: 2012-07-31End: 2014-11-30Updated: 2014-11-24

Phase 3

Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer

CompletedNCT00002967

NSABP Foundation IncBreast Cancer

Start: 1997-05-31End: 2006-03-31Updated: 2013-06-21